NEW YORK – DiaSorin announced on Friday that it has expanded its strategic partnership with diagnostics developer MeMed providing it with rights to distribute the MeMed BV immunoassay in the Italian market. The 15-minute BV test enables rapid differentiation between bacterial and viral infections to support antimicrobial stewardship.
Financial terms of the partnership were not disclosed.
Under the alliance, DiaSorin will distribute the BV test through its DiaSorin Italia subsidiary in decentralized healthcare settings. It will offer it on its Liaison XL and Liaison XS platforms for high-throughput testing in centralized labs, as well as on the smaller footprint MeMed Key point-of-need system in decentralized settings.
The CE-marked and US Food and Drug Administration-cleared MeMed BV test enables rapid differentiation between bacterial and viral infections to support antimicrobial stewardship. It integrates artificial intelligence algorithms to measure the host immune response proteins TRAIL2, IP-103, and C-reactive protein.
The BV test has been validated in multinational, double-blind clinical studies and real-world settings on over 20,000 patients in Italy, Israel, the United States, and other European countries, DiaSorin said in a statement, demonstrating over 90 percent sensitivity and specificity in differentiating between bacterial and viral infections.
DiaSorin previously inked a licensing deal with Haifa, Israel-based MeMed in 2020 to commercialize the BV test on the DiaSorin Liaison analyzer system, and the Liaison version of the test received FDA clearance in 2021.
MeMed closed a $93 million private financing round in 2022 and said it would use the funds to scale up manufacturing and accelerate commercialization of the MeMed BV and MeMed COVID-19 Severity tests. And earlier this year, it signed an agreement to develop and co-promote the MeMed BV assay for use with Beckman Coulter's Access line of immunoassay analyzers.